Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Recursion’s REC-994 Passes Phase II, But Needs To Find Right Dosage, Endpoints For Next Study

Sep 03 2024

• By Alaric DeArment

• Source: Shutterstock

Related Content

What’s The Key To Successful R&D With Artificial Intelligence? ‘Bilingual’ Scientists

May 03 2024

With First IND, Recursion Readies Its AI, Experimental Biology Approach For The Clinic

Jul 17 2018

Roche And Recursion’s AI Drug Discovery Pact To Focus On Neuroscience

Dec 08 2021

Bayer Switches Focus Of Recursion AI Pact To Oncology

Nov 13 2023

Related Companies

Recursion Pharmaceuticals, Inc.

Ovid Therapeutics, Inc.

Bayer AG

Roche Holding AG

Additional Topics

Artificial Intelligence Clinical Trials Research & Development Neurology BioPharmaceutical

More from AI

More from Digital Technologies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window